| P50 | author | Pedro J Garcia Ruiz | Q64795543 |
| | Félix Javier Jiménez-Jiménez | Q67215106 |
| | José Antonio Moreno Molina | Q67215108 |
| P2860 | cites work | Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine | Q28285331 |
| | Cinnarizine-induced parkinsonism in primates | Q28316206 |
| | Myoclonus of the legs as a complication of spinal morphine | Q28316851 |
| | Choreiform movements observed in an 8-year-old child following use of an oral theophylline preparation | Q28317170 |
| | Veralipride-induced tardive dystonia in a patient with bipolar psychosis | Q28317224 |
| | A case of choreoathetoid movements induced by anticholinergic drugs, trihexyphenidyl HCl and dosulepin HCl | Q28317298 |
| | Acute dystonia caused by fluoxetine | Q28317883 |
| | Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility | Q28318447 |
| | Zonisamide induced tremor--report of two cases | Q28319476 |
| | Report of a case of phenobarbital-induced dystonia | Q28319483 |
| | A case of parkinsonism induced by an oral contraceptive | Q28319544 |
| | Extrapyramidal symptoms in a patient treated with fluvoxamine | Q28319794 |
| | Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease | Q28320193 |
| | Acute dystonia due to amitriptyline | Q28320195 |
| | Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine | Q28320640 |
| | Chorea precipitated by sulphasalazine | Q28322687 |
| | Oral Facial Dyskinesia Associated with Prolonged Use of Antihistaminic Decongestants | Q28323388 |
| | Acute lithium-induced parkinsonism precipitated by liquid protein diet | Q28323643 |
| | Gilles de la Tourette syndrome after long-term chlorpromazine therapy | Q28323767 |
| | Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease | Q28324320 |
| | Sodium valproate in the treatment of levodopa-induced dyskinesia | Q28324464 |
| | Clenbuterol-Induced Tardive Dyskinesia | Q28324716 |
| | Acute Dystonia Induced by Sulpiride | Q28324718 |
| | Levodopa-associated hemifacial dystonia | Q28325153 |
| | Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine | Q28325492 |
| | Hormone replacement therapy induced chorea | Q28327095 |
| | Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects | Q28327576 |
| | Choreiform movements induced by anticholinergic therapy | Q28327676 |
| | Acute choreoathetoid reaction to propofol | Q28327932 |
| | Opiate therapy and self-harming behavior in Tourette's syndrome | Q28328340 |
| | Phenytoin-induced choreoathetosis | Q28328820 |
| | Acute dystonia induced by midazolam and abolished by flumazenil | Q28329318 |
| | Dyskinesia-an unusual reaction to ethosuximide | Q28329542 |
| | Methylphenidate-induced chorea: Case report and pharmacologic implications | Q28330165 |
| | Chorea induced by oral contraceptives | Q28330272 |
| | Tricyclic-induced myoclonus | Q28330423 |
| | Myoclonus caused by a tricyclic antidepressant | Q28330890 |
| | Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? | Q28331516 |
| | A case of childhood choreoathetosis induced by diphenylhydantoin | Q28331610 |
| | Persistent dystonia associated with buspirone | Q28332132 |
| | Acute dystonia due to clozapine | Q28378477 |
| | Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. | Q30459974 |
| | Disabling parkinsonism due to lithium: a case report | Q30465145 |
| | Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms | Q30466047 |
| | Phenytoin and dyskinesias: a report of two cases and review of the literature | Q30467442 |
| | A study of the early signs of drug induced parkinsonism | Q33590730 |
| | Tardive dystonia in a psychiatric hospital | Q33628680 |
| | Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa | Q33631368 |
| | Tardive dyskinesia and anticholinergic drugs. A critical review of the literature | Q34164780 |
| | Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias | Q34172000 |
| | Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. | Q34303593 |
| | Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. | Q34310822 |
| | Tardive tourettism after exposure to neuroleptic therapy | Q34391767 |
| | Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor | Q34616717 |
| | Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia | Q34631757 |
| | Lithium tremor | Q34720650 |
| | Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets | Q34729255 |
| | Toxic confusional state and choreiform movements after treatment with anabolic steroids | Q34781538 |
| | Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiology | Q35228641 |
| | Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases | Q35243267 |
| | Gender differences in tardive dyskinesia: a critical review of the literature | Q35271031 |
| | NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES | Q35467498 |
| | A review of 32 cases of tardive dystonia | Q36506008 |
| | Penicillin encephalopathy | Q36770938 |
| | Low plasma iron status and akathisia | Q36939570 |
| | Serum iron and transferrin in acute neuroleptic induced akathisia | Q36946600 |
| | Buspirone in the treatment of levodopa induced dyskinesias | Q36946985 |
| | Transitory procaine-induced Parkinsonism | Q37074890 |
| | Choreoathetosis: a sign of lithium toxicity | Q38263647 |
| | Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life | Q38572836 |
| | Metoclopramide-induced movement disorders. Clinical findings with a review of the literature | Q38721543 |
| | Motor complications associated with chronic levodopa therapy in Parkinson's disease. | Q38726323 |
| | Oral-buccal dyskinesia symptoms associated with low-dose benzodiazepine treatment | Q39220769 |
| | Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group | Q39230402 |
| | Flunarizine- and cinnarizine-induced extrapyramidal reactions | Q42218052 |
| | Bromocriptine-induced myoclonus | Q42218053 |
| | Forms of dystonia in patients with Parkinson's disease | Q42218373 |
| | Myoclonus and episodic delirium associated with phenelzine: a case report | Q42218952 |
| | Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy | Q42219539 |
| | Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine. | Q42220562 |
| | Choreoathetosis as toxic effect of lithium treatment | Q42223189 |
| | Myoclonic seizures after abrupt withdrawal from phenelzine and alprazolam. | Q42223542 |
| | Physostigmine-induced myoclonus in Alzheimer's disease | Q42223649 |
| | Occurrence of myoclonus in patients treated with cyclic antidepressants | Q42224093 |
| | Tics with combined thioridazine-methylphenidate therapy: case report | Q42226424 |
| | Abnormal involuntary movements induced by anticholinergic therapy | Q42230890 |
| | Physostigmine in choreiform movement disorders | Q42232127 |
| | Penicillin neurotoxicity | Q42236431 |
| | Parkinsonism Syndrome Due to Cephaloridine | Q42237594 |
| | Pseudodegenerative Disease Due to Diphenylhydantoin Intoxication | Q42238480 |
| | Central nervous system toxicity secondary to massive doses of penicillin 'G' in the treatment of overwhelming infections. | Q42240227 |
| | Choreic Movements Induced by the Use of Methadone | Q42240989 |
| | Drug-induced parkinsonism in the elderly | Q42242547 |
| | Parkinsonism associated with intraventricular amphotericin B. | Q42253187 |
| | Parkinsonian side effects induced by a monoamine oxidase inhibitor | Q42255204 |
| | Myoclonic seizures following chlorambucil overdose | Q42257454 |
| | Valproate tremors | Q42257985 |
| | Metoclopramide-induced Parkinsonism. Clinical characteristics of ten cases | Q42264427 |
| | Pemoline-induced chorea | Q42266932 |
| | An extrapyramidal syndrome after lithium therapy | Q42271854 |
| | Chlorambucil neurotoxicity: report of two cases | Q42272789 |
| | Levodopa-induced dyskinesias are improved by fluoxetine | Q42274453 |
| | Parkinson syndrome induced by veralipride | Q42274456 |
| | Increased incidence of levodopa therapy following metoclopramide use. | Q42274850 |
| | Spectrum of EEG abnormalities during clozapine treatment | Q42275319 |
| | Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. | Q42275434 |
| | Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. | Q42275576 |
| | Verapamil-induced parkinsonism | Q42276334 |
| | Prolonged myoclonus and meningism following propofol | Q42276603 |
| | Extrapyramidal side effects of clozapine and haloperidol | Q42276817 |
| | “Off” painful dystonia in Parkinson's disease treated with botulinum toxin | Q42277562 |
| | Myoclonus in patients treated with clozapine: a case series | Q42277782 |
| | Parkinsonism induced or worsened by cisapride | Q42278720 |
| | Myoclonus associated with lorazepam therapy in very-low-birth-weight infants | Q42278800 |
| | Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. | Q42279252 |
| | Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine | Q42280141 |
| | Diphenhydramine-induced acute dystonia. | Q42282137 |
| | Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia, and schizencephaly | Q42282316 |
| | Predictors of acute dystonia in first-episode psychotic patients. | Q42282739 |
| | Choreiform movements associated with the use of valproate | Q42283311 |
| | A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride | Q42283454 |
| | Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease | Q42283662 |
| | Persistent dystonia associated with carbamazepine therapy: a case report | Q42284174 |
| | Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking | Q42284272 |
| | Choreoathetosis induced by diphenylhydantoin in and infant with CHARGE syndrome | Q28332646 |
| | Extrapyramidal side effects with lithium treatment | Q28332672 |
| | Baclofen therapy may be associated with chorea in Alzheimer's disease | Q28332761 |
| | Chronic hemidystonia following acute dystonic reaction to thiethylperazine | Q28332893 |
| | Extrapyramidal symptoms upon discontinuation of fluoxetine | Q28332928 |
| | Propofol in myotonic dystrophy | Q28333014 |
| | Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea | Q28333107 |
| | Persistent dyskinesia in a patient receiving fluoxetine | Q28333220 |
| | Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine | Q28333282 |
| | Dystonia and reflex sympathetic dystrophy induced by ergotamine | Q28333539 |
| | Cocaine as a risk factor for acute dystonic reactions | Q28333547 |
| | Fluoxetine and parkinsonism in patients taking carbamazepine | Q28333630 |
| | Propanolol for fluoxetine-induced akathisia | Q28333728 |
| | Sulpiride-induced tardive dystonia | Q28334124 |
| | Neurologic approach to drug-induced movement disorders: a study of 125 patients | Q28334190 |
| | Prevalence of neuroleptic-induced dystonia in mania and schizophrenia | Q28334258 |
| | Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile | Q28334703 |
| | Cocaine withdrawal dystonia | Q28334760 |
| | A case of Tourette syndrome developing during haloperidol treatment | Q28335001 |
| | Acute dystonic reaction induced by a monoamine oxidase inhibitor | Q28335013 |
| | Domperidone-induced acute dystonia and polycystic ovary syndrome | Q28335075 |
| | Acute dystonia after alfentanil in untreated Parkinson's disease | Q28335125 |
| | Cocaine-associated multifocal tics | Q28335146 |
| | Adverse consequences of fluoxetine-MAOI combination therapy | Q28335253 |
| | Myoclonic encephalopathy caused by propafenone | Q28335322 |
| | Eye tics and subjective hearing impairment during fluoxetine therapy | Q28335397 |
| | Tardive dyskinesia induced by sulpiride | Q28335414 |
| | Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics | Q28335688 |
| | Levodopa-induced myoclonus | Q28336280 |
| | The effects of combining carbidopa with levodopa for Parkinson's disease | Q28336921 |
| | Treatment of Parkinson's disease with aporphines. Possible role of growth hormone | Q28336989 |
| | Metoclopramide-induced parkinsonism | Q28339157 |
| | Deanol in the treatment of levodopa-induced dyskinesias | Q28339746 |
| | Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs | Q28340091 |
| | Myoclonic spasms after epidural diamorphine infusion. | Q51710937 |
| | Acute dystonic reaction to crack cocaine. | Q51715740 |
| | Diphenhydramine-induced dystonia. | Q51751532 |
| | Cocaine and Tourette's syndrome. | Q51773809 |
| | Tardive dyskinesia prevalence rates during a ten-year follow-up. | Q52015706 |
| | Antipsychotic drugs and tardive dyskinesia: preliminary results in an adolescent psychiatric ward | Q52017408 |
| | Motor and mental side effects of clozapine. | Q52023745 |
| | Clozapine-related tardive dyskinesia. | Q52025914 |
| | The prevalence of akathisia in patients receiving stable doses of clozapine. | Q52027548 |
| | Tardive dyskinesia in elderly psychiatric patients: a 5-year study | Q52041980 |
| | A case of tardive Tourette-like syndrome | Q52045375 |
| | The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. | Q52051684 |
| | Natural history and treatment of tardive dystonia. | Q52081039 |
| | Bismuth myoclonic encephalopathies. Their course and lasting or definitive late complications | Q52239289 |
| | Induction of parkinsonism by intraventricular bethanechol in a patient with Alzheimer's disease. | Q53187667 |
| | Bromocriptine in Parkinsonism. | Q54333277 |
| | Tourette-like symptoms following chronic neuroleptic therapy | Q54423984 |
| | Tricyclic antidepressant poisoning. Reversal of coma, choreoathetosis, and myoclonus by physostigmine | Q54544324 |
| | Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. | Q55063992 |
| | Tardive Dyskinesia | Q56225963 |
| | Acute lithium toxicity--chorea, hypercalcemia and hyperamylasemia | Q57226909 |
| | Clinical Characteristics and Predisposing Factors in Acute Drug-Induced Akathisia | Q57725442 |
| | Tardive and chronically recurrent oculogyric crises | Q57725464 |
| | Acute drug-induced akathisia is not associated with low serum iron status | Q57725477 |
| | Fluoxetine-related indifference and akathisia. A case report | Q59389049 |
| | [Extrapyramidal side effects after long-term treatment with thiethylperazine] | Q60684302 |
| | Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics | Q61814473 |
| | Prednimustine-Induced Myoclonus—a Report of Three Cases | Q61917313 |
| | [Neurological side effects after using thiethylperazine] | Q64764449 |
| | Lisuride in the treatment of parkinsonism | Q64767891 |
| | Treatment of advanced Parkinson disease with pergolide | Q64785708 |
| | Letter: Encephalopathies due to insoluble salts of bismuth | Q66961466 |
| | Increased tardive dyskinesia in alcohol-abusing schizophrenic patients | Q67514455 |
| | Prospective study of neuroleptic-induced dystonia in mania and schizophrenia | Q67515054 |
| | Tardive tremor | Q67515245 |
| | Parkinsonism associated with calcium channel blockers: a prospective follow-up study | Q67516130 |
| | Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia | Q67525615 |
| | Tardive dyskinesia associated with use of metoclopramide in a child | Q67590605 |
| | Effects of remoxipride on measures of psychological performance in healthy volunteers | Q67649876 |
| | Flunarizine-induced akathisia | Q67844080 |
| | Tardive dyskinesia and diabetes mellitus | Q67889066 |
| | Parkinsonian syndrome during a treatment with veralipride | Q67917301 |
| | Acute dystonia due to neuroleptics in the treatment of vertigo: apropos 2 cases | Q67917531 |
| | Prevention of metoclopramide-induced akathisia during gastric emptying imaging | Q67941566 |
| | Chlorambucil-induced myoclonic seizures in an adult | Q42624107 |
| | Reversible parkinsonism related to meperidine | Q42630180 |
| | Hazards of high-dose meperidine | Q42631878 |
| | Nifedipine and myoclonic dystonia | Q42631963 |
| | Atypical acute dystonia associated with trazodone treatment | Q42645110 |
| | Chorea-like syndrome induced by alpha-methyldopa | Q42656865 |
| | Dystonic reactions to amitriptyline and doxepin | Q42660787 |
| | Acute dystonic reaction to cocaine | Q42661358 |
| | Parkinsonism induced by pyridostigmine | Q42666382 |
| | Myoclonus during combined tricyclic antidepressant and lithium treatment | Q42670973 |
| | Lithium-induced akathisia | Q42674418 |
| | Naloxone withdrawal exacerbates Tourette syndrome | Q42679802 |
| | Reversible chorea due to ranitidine and cimetidine | Q42682989 |
| | Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. | Q42691933 |
| | Diphenhydramine and acute dystonia | Q42695465 |
| | Tryptophan antagonism of stimulant-induced tics | Q42698017 |
| | Dystonia--a rare manifestation of carbamazepine toxicity | Q43238696 |
| | Flunarizine-induced parkinsonism: clinical report | Q43461662 |
| | Neuroleptic-induced tardive dyskinesias in France | Q43467958 |
| | Clozapine-induced myoclonic jerks and drop attacks | Q43496832 |
| | Antidepressant-related akathisia | Q43553914 |
| | Neonatal choreoathetosis following prenatal exposure to oral contraceptives | Q43593109 |
| | Parkinsonism induced by indeloxazine hydrochloride in the elderly. | Q43596551 |
| | Prevalence of tardive dystonia | Q43616946 |
| | Acute dystonic reactions and long-lasting impaired consciousness associated with oxatomide in children | Q43624895 |
| | Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? | Q43641811 |
| | Sertraline Does Not Alter Steady-State Concentrations or Renal Clearance of Lithium in Healthy Volunteers | Q43705439 |
| | Tardive dyskinesia in elderly psychiatric patients in Singapore | Q43746311 |
| | Useless drugs are not placebos: lessons from flunarizine and cinnarizine | Q43789227 |
| | Morvan's chorea caused by treatment with gold salts | Q43836024 |
| | Tardive dyskinesia in schizophrenics under 60 years of age. | Q43861228 |
| | "Rubral" tremor induced by a neuroleptic drug | Q43921915 |
| | Three cases of action myoclonus during treatment with imipramine and amitriptyline | Q44033046 |
| | Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis | Q44097501 |
| | Diltiazem-induced myoclonus | Q44151260 |
| | High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics | Q44218472 |
| | A survey of tardive dyskinesia in psychiatric inpatients in Japan | Q44253421 |
| | Risk factors for tardive dyskinesia according to primary psychiatric diagnosis | Q44293796 |
| | Changes in somatosensory evoked potentials in pharmacogenic myoclonia | Q44313390 |
| | Prevalence of Tardive Dyskinesia Among Three Ethnic Groups of Chronic Psychiatric Patients | Q44354355 |
| | Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis | Q44366605 |
| | Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study | Q44404587 |
| | Parkinsonism induced by indeloxazine hydrochloride | Q44414589 |
| | Movement disorders induced by drugs: experience at a pharmaco-vigilance center over five years | Q44539312 |
| | Fluoxetine-induced akathisia in male OCD patients. | Q44551830 |
| | Tardive dyskinesia associated with molindone treatment. | Q44556345 |
| | A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases | Q44558227 |
| | More on metoclopramide and tardive dyskinesia | Q44697647 |
| | Low serum iron in patients with neuroleptic-induced akathisia and dystonia under antipsychotic drug treatment | Q44772331 |
| | Choreoathetosis induced by verapamil and lithium treatment | Q44841029 |
| | Does fluoxetine exacerbate Parkinson's disease? | Q44872549 |
| | Dystonic reaction associated with sumatriptan | Q72498859 |
| | Anticholinergics and dyskinesia | Q72519822 |
| | [Myoclonia in patients treated with tricyclic antidepressive agents. Prospective evaluation] | Q72530425 |
| | Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs | Q72540335 |
| | Dyskinesia associated with fluvoxamine | Q72573032 |
| | Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease | Q72585179 |
| | An alert to extrapyramidal side-effects from SSRIs | Q72588097 |
| | [Chorea-athetosis syndrome under the effect of carbamazepine and viloxazine. Consequence of drug interaction?] | Q72600650 |
| | Akathisia in association with nortriptyline therapy | Q72601017 |
| | Akathisia and sertraline | Q72639386 |
| | Lithium neurotoxicity at subtherapeutic serum levels | Q72672164 |
| | [Neurological complications caused by gold salts. Nosologic report apropos of a case] | Q72683767 |
| | [Fluoxetine and extrapyramidal symptoms. Two case reports] | Q72692988 |
| | Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient | Q72694935 |
| | Sertraline and extrapyramidal side effects | Q72747085 |
| | Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism | Q72759239 |
| | Clozapine in tardive dyskinesia: observations from human and animal model studies | Q72808154 |
| | Clozapine, negative symptoms, and extrapyramidal side effects | Q72808241 |
| | Sertraline and akathisia | Q72810755 |
| | A reversible parkinsonian syndrome and hepatotoxcity following addition of carbamazepine to sodium valproate | Q72856331 |
| | Metoclopramide-induced extra pyramidal symptoms in a diabetic patient | Q72864471 |
| | Sertraline-induced akathisia | Q72887765 |
| | Dystonic reaction associated with fluvoxamine | Q72887767 |
| | Akathisia with clozapine | Q72927664 |
| | Akathisia and clozapine treatment | Q72932721 |
| | A survey of drug-induced extrapyramidal reactions | Q78781182 |
| | Drug-induced parkinsonism in a movement disorders unit: A four-year survey | Q81554064 |
| | [Parkinsonism possibly caused by cinnarizine] | Q93662577 |
| | Meperidine and reversible parkinsonism | Q95415451 |
| | Dystonia and reflex sympathetic dystrophy induced by ergotamine | Q95814395 |
| | [Extrapyramidal movement disorders following the use of flunarizine] | Q67960072 |
| | Prevalence and severity of akathisia in patients on clozapine | Q67968722 |
| | Buspirone and dyskinesia | Q67980790 |
| | Tricyclics, akathisia, and jitteriness | Q68002137 |
| | Akathisia associated with buspirone | Q68002140 |
| | Flunarizine-induced parkinsonism in the elderly | Q68014204 |
| | Cocaine and chorea | Q68028356 |
| | [Domperidone and Parkinson disease] | Q68041241 |
| | Methsuximide-induced movement disorder | Q68065769 |
| | Extrapyramidal symptoms in neuroleptic recipients | Q68084960 |
| | Persistent dystonia possibly induced by flecainide | Q68086719 |
| | Parkinsonian syndrome after long-term treatment with clebopride | Q68086723 |
| | Serotonin syndrome from trazodone and buspirone | Q68087361 |
| | Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients | Q68087931 |
| | Factors in the development of severe forms of tardive dyskinesia | Q68093683 |
| | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia | Q68161612 |
| | A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia | Q68161616 |
| | Experiences of long-term treatment with remoxipride: efficacy and tolerability | Q68161624 |
| | Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study | Q68161672 |
| | Relationship of neuroleptic-induced akathisia to drug-induced parkinsonism | Q68165103 |
| | Acute dystonic reaction in normal humans caused by catecholamine depletion | Q68165663 |
| | [A case report of captopril-induced parkinsonism] | Q68170378 |
| | Parkinson-like side effects during prolonged treatment with flunarizine | Q68203847 |
| | An unusual cause of recurrent chorea | Q68268127 |
| | Methysergide-induced akathisia | Q68285930 |
| | Oral contraceptives causing chorea in a young woman | Q68296686 |
| | Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients | Q68316409 |
| | Drug-induced parkinsonism: relationship to age at onset of schizophrenia | Q68317865 |
| | Prospective study of tardive dyskinesia incidence in the elderly | Q68318857 |
| | Acute Extrapyramidal Syndromes in Neuroleptic-Treated Elders: A Pilot Study | Q68333254 |
| | Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated? | Q68393899 |
| | Neurologic complications of metoclopramide therapy | Q68474111 |
| | Chorea as the initial presentation of oral contraceptive induced systemic lupus erythematosus | Q68508878 |
| | Acute dystonia and fluoxetine | Q68585405 |
| | Possible adverse effects of buspirone when used with other psychotropic drugs | Q68631853 |
| | Pemoline-induced abnormal involuntary movements | Q68676333 |
| | Eosinophilia-myalgia syndrome with myoclonic jerks | Q68687628 |
| | Long-term neurologic complications of metoclopramide | Q68726437 |
| | Akathisia and fluoxetine | Q68775311 |
| | Lithium-associated tardive dyskinesia | Q68789226 |
| | [Myoclonic encephalopathy caused by bismuth] | Q68821787 |
| | Tardive myoclonus | Q68844030 |
| | Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients | Q69372145 |
| | Buspirone revisited | Q69372595 |
| | A comparison of severe tardive dystonia and severe tardive dyskinesia | Q69374995 |
| | [A severe dystonic reaction in acute Torecan poisoning] | Q69377174 |
| | Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy | Q69377629 |
| | [Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade--report of 31 cases] | Q69384242 |
| | Myoclonus during a course with buflomedil treatment | Q69422308 |
| | Jerk-locked averaging and somatosensory evoked potential in tricyclic-induced myoclonus: a case report | Q69468635 |
| | Orofacial dyskinesias associated with lorazepam therapy | Q69544070 |
| | [Acute dystonic reaction due to domperidone in a infant] | Q69547244 |
| | Persistent tardive dyskinesia associated with amoxapine therapy | Q69562176 |
| | Hemichorea induced by oral contraceptive use | Q69639295 |
| | A dystonic reaction occurring during treatment with tranylcypromine | Q69639812 |
| | Myoclonic encephalopathy caused by bismuth | Q69643877 |
| | "Chorée fibrillaire de Morvan" followed by Guillain-Barré syndrome in a patient receiving gold therapy | Q69657979 |
| | [Myoclonic encephalopathy caused by bismuth salts. Efficacy of treatment with dimercaprol] | Q69705017 |
| | Involuntary movements associated with mianserin treatment. A case report | Q69718854 |
| | Trimipramine and dopamine receptor blockade | Q69752120 |
| | Tardive dyskinesia induced by sulpiride in a patient with hypothyroidism | Q69782340 |
| | Tardive Tourette's syndrome treated with clonidine and mesoridazine | Q69861377 |
| | Tardive dyskinesia in the elderly | Q69885415 |
| | Early versus late onset psychosis and tardive dyskinesia | Q69886833 |
| | Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics | Q69892944 |
| | Tardive myoclonus | Q69893374 |
| | Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population | Q69896201 |
| | Neuroleptic-induced parkinsonism in older schizophrenics | Q69897469 |
| | The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies | Q69899192 |
| | Low serum iron status and akathisia | Q69899823 |
| | Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity | Q69901314 |
| | Clinical forms of severe tardive dyskinesia | Q69902387 |
| | Coexistent tardive dyskinesia and parkinsonism | Q69911818 |
| | Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia | Q69926625 |
| | Nifedipine and myoclonic disorders | Q69944564 |
| | Tardive dyskinesia associated with metoclopramide | Q70013422 |
| | Metoclopramide-induced tardive dyskinesia: a case report | Q70029778 |
| | [Encephalopathy caused by bismuth has not disappeared...]. | Q70032965 |
| | [Myoclonic encephalopathy probably attributable to propafenone] | Q70050422 |
| | [Myoclonic and convulsive encephalopathy caused by bismuth. Usefulness of dimercaprol treatment] | Q70116273 |
| | Extrapyramidal syndrome during treatment with flunarizine | Q70256108 |
| | [Veratramine-induced myoclonus] | Q70269431 |
| | Metoclopramide-induced akathisia | Q70371391 |
| | [Neurologic symptoms in lithium poisoning] | Q70382402 |
| | Tardive dyskinesia-like syndromes with clomipramine | Q70523182 |
| | Drug-induced parkinsonism: a growing list | Q70528593 |
| | Persistent parkinsonism and tardive dyskinesia induced by clebopride | Q70662821 |
| | Case report of probable sertraline-induced akathisia | Q70717678 |
| | Fluvoxamine and mandibular dystonia | Q70866311 |
| | Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders | Q71095691 |
| | Pharmacological and Clinical Problems of Lithium Prophylaxis | Q71524833 |
| | Fluoxetine, buspirone, myoclonus, and dystonia | Q71553502 |
| | Brain damage and tardive dyskinesia | Q71579746 |
| | Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation | Q71634080 |
| | [Morphine-induced hyperalgesia, allodynia and myoclonus--new side-effects of morphine?] | Q71704316 |
| | Risperidone and tardive dyskinesia: a case report | Q71742965 |
| | Familial acute dystonic-dyskinetic syndrome with dominant inheritance after use of antidopaminergic antiemetic drugs | Q71758669 |
| | Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years | Q71780119 |
| | [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance] | Q71836825 |
| | Adverse events in PTSD patients taking fluoxetine | Q71933640 |
| | Diltiazem-induced acute parkinsonism | Q71993012 |
| | Does fluoxetine aggravate Parkinson's disease? A pilot prospective study | Q72000199 |
| | The serotonin syndrome in a patient receiving sertraline after an ankle block | Q72012848 |
| | Transient Gilles de la Tourette syndrome after chronic neuroleptic withdrawal | Q72017903 |
| | Tardive dyskinesia with Tourette-like syndrome | Q72018108 |
| | Neuroleptic Associated Tardive Dyskinesias in Young People with Psychoses | Q72032674 |
| | Tourette-like syndrome after long-term neuroleptic drug treatment | Q72049034 |
| | Adverse reaction to metoclopramide during enteroclysis | Q72074482 |
| | Pallidotomy for Parkinson's Disease | Q72110838 |
| | [Myoclonus in rest and exertion induced by piperazine] | Q72126404 |
| | [Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome] | Q72138737 |
| | Valproic acid treatment of clozapine-induced myoclonus | Q72174496 |
| | Persistent tardive dyskinesia: demographic and pharmacological risk factors | Q72209010 |
| | Clozapine and tardive dystonia | Q72209194 |
| | Diabetes and development of tardive dyskinesia | Q72219032 |
| | Drug-induced movement disorders | Q72221415 |
| | Paroxetine and akathisia | Q72233606 |
| | Does clozapine cause tardive dyskinesia? | Q72234244 |
| | [Neuroleptic-induced dysphoric response in non-schizophrenic patients] | Q72235550 |
| | Akathisia in a cancer patient treated with antiemetics | Q72248882 |
| | [Psychotropic drug-induced myoclonus] | Q72265080 |
| | Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease | Q72276938 |
| | Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease | Q72319710 |
| | [Confusion syndrome, myoclonus and treatment with pefloxacin] | Q72324535 |
| | Sertraline and akathisia | Q72339058 |
| | Apomorphine and diphasic dyskinesia | Q72343778 |
| | [Patient care in a hospital based unit for treating Parkinson's disease and movement disorders: a 3-year prospective study] | Q72363777 |
| | Antiemetic-induced akathisia in cancer patients receiving chemotherapy | Q72382748 |
| | Parkinsonism and tardive dyskinesia after chronic use of clebopride | Q72383875 |
| | Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis | Q72390955 |
| | Involuntary movement disorders associated with felbamate | Q72415611 |
| | Tardive Tourette syndrome | Q72421633 |
| | Theoretical and Clinical Aspects of the Tourette Syndrome (Chronic Multiple Tic) | Q72433696 |
| | Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol) | Q72451511 |
| | Tardive dyskinesia-like syndrome associated with lithium and carbamazepine | Q72467684 |
| | Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment | Q72476525 |
| | Lorazepam in the treatment of lithium-induced akathisia | Q28340727 |
| | Transient Parkinson syndrome and tremor caused by the use of sodium valproate | Q28340908 |
| | Carbamazepine-induced tics | Q28342073 |
| | Dyskinesias Associated with Tricyclic Antidepressants | Q28342577 |
| | Parkinson syndrome, a possible adverse effect of calcium inhibitors | Q28342840 |
| | Fluoxetine-induced akathisia: clinical and theoretical implications | Q28342853 |
| | Bromazepam-induced dystonia | Q28342855 |
| | Norpethidine induced myoclonus in a patient with renal failure | Q28354367 |
| | Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine | Q28361104 |
| | Acute dystonic reaction with asterixis and myoclonus following metoclopramide therapy | Q28361191 |
| | Unusual idiosyncratic reactions to carbamazepine | Q28361254 |
| | Aggravation of Parkinson's disease by cinnarizine | Q28361426 |
| | Generalised chorea due to digoxin toxicity | Q28361488 |
| | Clonazepam-induced Tourette syndrome in a subject with hyperexplexia | Q28361636 |
| | Extrapyramidal reactions with metoclopramide | Q28362373 |
| | Development of Extrapyramidal Symptoms in Hypertensive Patients Treated with Diazoxide | Q28363946 |
| | Generalized choreiform movements as a complication of methyldopa therapy in chronic renal failure | Q28367017 |
| | Chorea in digoxin toxicity | Q28367080 |
| | Adverse neurologic effects of metoclopramide | Q28367772 |
| | Drug points: Exacerbation of idiopathic Parkinson's disease by naproxen | Q28367952 |
| | Cocaine induced chronic tics | Q28369442 |
| | Myoclonus associated with propafenone | Q28378472 |
| | Persistent movement disorders induced by buspirone | Q42284511 |
| | Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology | Q42285088 |
| | Buspirone in levodopa-induced dyskinesias | Q42285208 |
| | Paroxysmal kinesigenic dystonia after methylphenidate administration | Q42285242 |
| | Reversible valproate-induced extrapyramidal disorders | Q42285309 |
| | Reversal of amphotericin-B-related encephalopathy | Q42286063 |
| | Parkinsonian syndrome in childhood after sodium valproate administration. | Q42286314 |
| | Bromocriptine-induced dystonia in patients with aphasia and hemiparesis | Q42286539 |
| | Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine | Q42287163 |
| | Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine | Q42287448 |
| | Morphine-induced myoclonic movements in a pediatric pain patient | Q42287760 |
| | Fluoxetine and tics in an adolescent | Q42287926 |
| | Carbamazepine-induced tics | Q42289132 |
| | Increase of Parkinson disability after fluoxetine medication | Q42289259 |
| | Neuropsychiatric toxicity of phenytoin. Importance of monitoring phenytoin levels | Q42289310 |
| | Infantile chorea following abrupt withdrawal of diazepam and pentobarbital therapy | Q42289317 |
| | Calcium permeability changes and neurotransmitter release in cultured brain neurons. II. Temporal analysis of neurotransmitter release | Q42437019 |
| | Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: Neurological and electroencephalographic prospective study | Q42461146 |
| | Development of transmitter-releasing capacity in neuron-enriched tissue cultures | Q42487642 |
| | Phenytoin-induced focal chorea | Q42554551 |
| | Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. | Q42556717 |
| | Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases | Q42557391 |
| | A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. | Q42557737 |
| | The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders | Q42558135 |
| | Parkinsonism unmasked by verapamil | Q42558223 |
| | Interaction between fluoxetine and neuroleptics | Q42558559 |
| | Cocaine-related movement disorders | Q42558632 |
| | Terfenadine-induced tremor | Q42559128 |
| | Fluoxetine-associated dystonia. | Q42560690 |
| | Disabling tremor after lamotrigine with sodium valproate | Q42562250 |
| | Midazolam and myoclonus in neonate | Q42562679 |
| | Dose-dependent stuttering and dystonia in a patient taking clozapine. | Q42562855 |
| | Exacerbation of parkinsonism caused by fluoxetine | Q42562961 |
| | Methamphetamine-induced choreoathetosis and rhabdomyolysis | Q42563079 |
| | Dystonia induced by amphetamine and haloperidol | Q42563252 |
| | Parkinsonism induced by amlodipine | Q42563737 |
| | Paroxetine-molindone interaction. | Q42564019 |
| | Possible serotonin syndrome with moclobemide and pethidine. | Q42565097 |
| | Tic-like syndrome after treatment with clozapine | Q42565856 |
| | Dystonia and drug-induced hepatitis in a patient treated with clozapine | Q42565857 |
| | A possible paroxetine withdrawal syndrome | Q42565862 |
| | Phenelzine and venlafaxine interaction | Q42566316 |
| | Unexpected dystonia while changing from clozapine to risperidone | Q42567887 |
| | Toxic interaction of venlafaxine and isocarboxazide | Q42571127 |
| | Exacerbation of parkinsonism by methyldopa | Q42571837 |
| | Parkinsonism and Tardive Dyskinesia Associated with Long-Term Metoclopramide Therapy | Q42574144 |
| | Amoxapine-induced chorea | Q42579647 |
| | Action myoclonus in lithium toxicity | Q42580546 |
| | Parkinsonism induced by methyldopa | Q42583011 |
| | Parkinsonism induced by phenytoin | Q42623690 |
| | An extrapyramidal choreiform syndrome caused by amphetamine addiction | Q39254343 |
| | Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms | Q39254779 |
| | Adverse effects of antihistamines | Q39419326 |
| | Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs | Q39469335 |
| | Chorea induced by the use of oral contraceptives. Report of a case and review of the literature | Q39483761 |
| | Oral dyskinesia associated with buspirone use in an elderly woman | Q39518723 |
| | Acute generalized myoclonus following buspirone administration. | Q39531690 |
| | Acute dystonic reaction due to diazepam | Q39558484 |
| | Myoclonic activity associated with cefmetazole, with a review of neurotoxicity of cephalosporins | Q39621354 |
| | Tourette-like syndrome following low dose short-term neuroleptic treatment | Q39720208 |
| | The pharmacology of foot dystonia in parkinsonism. | Q39757691 |
| | Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. | Q39778645 |
| | Anticonvulsant medications: an iatrogenic cause of tic disorders | Q39791909 |
| | Choreoathetosis associated with lithium: case report and literature review | Q40209949 |
| | The epidemiology of drug-induced akathisia: Part I. Acute akathisia. | Q40371439 |
| | The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. | Q40371444 |
| | Extrapyramidal side effects and tolerability of risperidone: a review | Q40391940 |
| | Stereotypic movements after lorazepam administration in premature neonates: a series and review of the literature | Q40435031 |
| | Drug-induced parkinsonism: a review. | Q40590287 |
| | An algorithm for the management of Parkinson's disease. | Q40591531 |
| | Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms | Q40622075 |
| | Drug-induced parkinsonism in the aged. Recognition and prevention | Q40644102 |
| | Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. | Q40679820 |
| | Clinical aspects of motor fluctuations in Parkinson's disease | Q40681290 |
| | Problems of epidural droperidol administration | Q40698080 |
| | Sertraline intoxication in a child | Q40699964 |
| | Postoperative myoclonus and rigidity after anesthesia with opioids | Q40728887 |
| | Chorea associated with oral contraception | Q40793484 |
| | Adverse effects of antipsychotic agents. Do newer agents offer advantages? | Q41060466 |
| | Pharmacological options for the management of dyskinesias | Q41258822 |
| | Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis | Q41314197 |
| | Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias | Q41347352 |
| | Tics in a patient with Parkinson's disease | Q41448939 |
| | The Nithsdale schizophrenia surveys. An overview | Q41788956 |
| | Diltiazem-induced parkinsonism | Q41870605 |
| | Chloroquine-Induced Acute Dystonic Reactions in the Presence of Metronidazole | Q41912141 |
| | Tagamet-induced acute dystonia | Q42081842 |
| | Transient chorea induced by phenytoin | Q42083055 |
| | Benztropine-induced acute dystonic reaction | Q42085040 |
| | Extrapyramidal reactions to metoclopramide and prochlorperazine | Q42192324 |
| | Metoclopramide-induced parkinsonism. | Q42192339 |
| | Movement disorders and depression due to flunarizine and cinnarizine | Q42198150 |
| | Parkinsonism and amiodarone therapy | Q42198346 |
| | Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome | Q42198925 |
| | A case of tuberculous pleurisy associated with myoclonus and Quincke's edema due to isoniazid and isoniazid sodium methanesulfonate | Q42199523 |
| | Akathisia associated with droperidol during epidural anesthesia | Q42199894 |
| | Neurologic effects of acyclovir after an allogenic marrow graft | Q42200661 |
| | Neuroleptic-induced tics in two hyperactive children | Q42201728 |
| | Acute dystonic reaction to bethanechol--a direct acetylcholine receptor agonist | Q42201793 |
| | Drug-induced dystonia in young and elderly patients | Q42202494 |
| | Drug-induced tremor of the tongue | Q42203236 |
| | Choreoathetosis induced by cyproheptadine | Q42203273 |
| | Unusual neurotoxicity associated with amiodarone therapy | Q42206553 |
| | Myoclonic seizures with lithium | Q42208440 |
| | Choreoathetotic movements in a patient with epilepsy after treatment with diphenylhydantoin | Q42208467 |
| | Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antidepressant-induced myoclonus | Q44918949 |
| | Pseudoephedrine accumulation in renal failure | Q45049611 |
| | Choreoathetotic movements: A possible side effect of gabapentin. | Q45096412 |
| | Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents | Q45164599 |
| | Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease | Q45194520 |
| | Tardive dyskinesia associated with high-dose intravenous metoclopramide | Q45250047 |
| | Neuroleptically induced dystonia in Huntington's disease: a case report | Q45295495 |
| | The effect of d-amphetamine on choreiform movement disorders | Q45302842 |
| | Prevalence of dystonia in veterans on chronic antipsychotic therapy | Q45336650 |
| | Metoclopramide and tardive dyskinesia. | Q45988511 |
| | Choreoathetoid disorder associated with amphetamine-like drugs | Q46156345 |
| | Temporary deterioration in parkinsonian signs after modest alcohol intake | Q46207583 |
| | The Results, Indications, and Physiology of Posteroventral Pallidotomy for Patients with Parkinson's Disease | Q46252722 |
| | Epidemiology of tardive dyskinesias in the Maghreb | Q46283226 |
| | Delayed appearance of facial tics following chronic fluphenazine administration to guinea pigs | Q46405444 |
| | Intermittent Tremor-Bursts Induced by Chlorpromazine and Pentobarbitone in Guinea Pigs: A New Tremor Model | Q46411856 |
| | Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan | Q46496661 |
| | Drug-induced myoclonus | Q46514758 |
| | Tardive dyskinesia in schizophrenics. Prevalence, distribution and relationship to neurological "soft" signs in Nigerian patients | Q46560030 |
| | The Ca++-antagonist nimodipine decreases and the Ca++-agonist Bay K 8644 increases catecholamine synthesis in mouse brain | Q46633981 |
| | Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports | Q46664600 |
| | Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong. | Q47264177 |
| | Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong | Q47287190 |
| | A prospective study of tardive dyskinesia in Japan | Q47330934 |
| | Serum iron abnormalities in neuroleptic-induced akathisia in schizophrenic patients | Q47564984 |
| | Dyskinesias possibly induced by norpseudoephedrine | Q48203663 |
| | Neuroleptic medications inhibit complex I of the electron transport chain | Q48298621 |
| | An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms | Q48308346 |
| | Brain atrophy and intellectual impairment in tardive dyskinesia | Q48327654 |
| | Does mianserin induce involuntary movements in brain damaged patients? | Q48379160 |
| | Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients | Q48464607 |
| | Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations | Q48611830 |
| | Behavioral stimulation associated with risperidone initiation | Q48812809 |
| | Massive carbamazepine overdose: Clinical and pharmacologic observations in five episodes | Q48958276 |
| | Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy | Q49133745 |
| | Drug-induced asterixis in Parkinson disease | Q49141763 |
| | Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration | Q50346457 |
| | Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor | Q51107835 |
| | The relationship between stimulant medication and tics. | Q51188050 |
| | Myoclonus with Trazodone | Q51189009 |
| | The coexistence of parkinsonism-like symptoms and tardive dyskinesia. | Q51250446 |
| | Oral midazolam and emergence delirium. | Q51601995 |
| | Dystonic-like reaction following cisapride therapy. | Q51615003 |
| | Paradoxical reaction to midazolam and control with flumazenil. | Q51644344 |
| | Neurological side effects related to valproate after neurosurgery. | Q51646231 |
| | Myoclonic spasms following intrathecal diamorphine. | Q51655376 |
| | Reversal of midazolam sedation. | Q51656251 |
| | Akathisia after long-term epidural use of droperidol: a case report | Q51686464 |
| | Acute choreoathetoid reaction to propofol. | Q51706425 |
| | Lithium-induced akathisia | Q42209348 |
| | Phenobarbital-induced Tourette-like symptoms | Q42209414 |
| | Acute dystonia from etoposide | Q42209667 |
| | Isoniazid therapy in Parkinson's disease | Q42211121 |
| | Opiate withdrawal unmasks Tourette's syndrome | Q42211299 |
| | Can trazodone induce parkinsonism? | Q42214232 |
| | Myoclonic spasms following intrathecal morphine | Q42214745 |
| | Successful Treatment of Levodopa-Induced Myoclonus and Levodopa Withdrawal-Induced Neuroleptic Malignant Syndrome | Q42214779 |
| | Anticholinergic-induced chorea in the treatment of focal dystonia | Q42216749 |
| | Parkinsonism induced by high-dose cytosine arabinoside | Q42216762 |
| | Oral contraceptive induced paraballism | Q42217887 |
| | Persistent tardive dyskinesia associated with amoxapine therapy--two case reports | Q68960035 |
| | Tricyclic-induced acute tardive dyskinesia. A case report | Q69043537 |
| | Myoclonus during treatment with clozapine and lithium: the role of serotonin | Q69153797 |
| | Nomifensine-induced orofacial dyskinesia and Sydenham's chorea | Q69219428 |
| | Extrapyramidal side-effects of flunarizine | Q69257905 |
| | Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease | Q69356679 |
| | The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital | Q69367819 |
| | Parkinsonism following neuroleptic withdrawal | Q69368509 |
| | Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters | Q69369827 |
| | Mitochondrial complex I deficiency in Parkinson's disease | Q69370277 |
| | ??? | Q67218795 |
| P433 | issue | 3 | |
| P921 | main subject | movement disorders | Q2608695 |
| P304 | page(s) | 180-204 | |
| P577 | publication date | 1997-03-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Drug-Induced Movement Disorders | |
| P478 | volume | 16 | |